App-Quantinova.ai

Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from two Phase 3 Studies

Xenofon Baraliakos - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

ABT-494

T-cell-Specific Biomarkers of Early Treatment Response in Patients with Rheumatoid Arthritis Treated with a Tumour Necrosis Factor Inhibitor

Megan A Sutcliffe - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

First-line tumour necrosis factor inhibitor (TNFi) treatment is associated with high multi-criteria remission early on compared to treat-to-target in a treatment naïve RA cohort

Rudresh Shukla - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Methotrexate

Inequity in Clinical Commissioning Group funding across England for high-cost biologic drugs in rheumatoid arthritis

Olivia Buckeldee - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Abatacept

Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients

Joanna McLorinan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Rheumatoid arthritis

Rituximab

Janus Kinase Inhibitors in Rheumatoid Arthritis Patients: Real-World Experience from a Regional Centre in UK

Adeola Ajibade - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

Periodontal assessment and treatment among individuals at-risk of rheumatoid arthritis: a qualitative study

Lara S Chapman - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Cytomegalovirus seropositivity is associated with an increased frequency of highly differentiated T effector memory cells re-expressing CD45RA (Temra) and persistent disease refractory to anti-TNF therapy in rheumatoid arthritis

Su-Ann Yeoh - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Rheumatoid arthritis

Abatacept

Socioeconomic deprivation is associated with reduced response and lower treatment persistence with anti-TNF therapies in people with rheumatoid arthritis

Sizheng Steven Zhao - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Association between musculoskeletal ultrasound and the Rheumatoid Arthritis Foot Disease Activity Index in managing the rheumatoid foot

Anika Hoque - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Pragmatic Biologic Tapering Combining Clinical and Ultrasound Assessment in Patients with Rheumatoid Arthritis in Routine Clinical Practice - Predictors of Failure from a Regional Centre in UK

Hafis Muhammed VK - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Long-term survival of patients with idiopathic inflammatory myopathies: Anatomy of a single-center cohort

Francisca Guimaraes - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Idiopathic inflammatory myopathies

N/A

An Exploratory Trial Assessing Finger Perfusion, Raynaud’s Condition Score and Safety, Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud's Phenomenon Secondary to Systemic Sclerosis

Ariane L Herrick - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Raynaud syndrome

Treprostinil

The Triptryium wilfordii derivative celastrol has anti-fibrotic effects in systemic sclerosis

Andrew Leask - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

celastrol

Allele-associated chromatin interactions in primary immune cells uncover mechanisms of gene regulation

David González-Serna - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Rituximab and tocilizumab and their effect on lung disease progression in scleroderma: a retrospective cohort study at a single centre

Nina R Goldman - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Tocilizumab

Real-world audit of patients with idiopathic inflammatory myositis-related interstitial lung disease in a European population

Aravinthan Loganathan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Function is impaired during patient-reported idiopathic inflammatory myopathy flares - results from a longitudinal smartphone-based study

Georgia Howard - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inclusion body myositis

N/A

Evidence of Type I interferon activation during vascular manifestations of systemic sclerosis

Stefano Di Donato - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Interferon

Distinct differences in complement perturbation between scleroderma-related interstitial lung disease with and without emphysema

Claire Beesley - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Filters

45280 Abstracts